Abstract
AbstractSARS‐CoV‐2 nucleocapsid (N) protein has been proposed as a good vaccine target. N‐specific T cells were observed in SARS‐CoV‐2 N immunized mice and COVID‐19 convalescents. It is of importance to identify the T cell responses triggered by SARS‐CoV‐2 N protein. Intradermal immunization with SARS‐CoV N protein was demonstrated to elicit non‐protective T cell responses which may be avoided by intranasal vaccination. Therefore, we conducted intranasal vaccination of BALB/c mice with recombinant adenovirus type‐5 expressing SARS‐CoV‐2 N protein. Such procedure induced CD8 T cell responses in the lung. Meanwhile CD4 T cell responses were observed in the spleen, which was associated with robust antibody production. Our study further supports the notion that SARS‐CoV‐2 N protein can work as a target for vaccine development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.